구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | anti-mesothelin CAR-T cells (anti-mesothelin CAR-T cells) UTC Therapeutics Inc.·Solid Tumor, Adult 23 trials |
|---|---|
Overview Program | anti-mesothelin CAR-T cells |
Overview Company | UTC Therapeutics Inc. |
Overview Modality | CGT |
Overview Target | Solid Tumor, Adult |
Overview Indication | Solid Tumor, Adult |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Biogenic Selenium Nanoparticles Potentiate Anti-Mesothelin CAR-T Cell Therapy in a Syngeneic TNBC Model.. Triple-negative breast cancer (TNBC) remains a highly aggressive subtype lacking effective targeted therapies. Although chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment of hematological malignancies, its efficacy in solid tumors is hindered by the immunosuppressive … |
Toxicology CRS | Reported |
Clinical Safety signal | Biogenic Selenium Nanoparticles Potentiate Anti-Mesothelin CAR-T Cell Therapy in a Syngeneic TNBC Model.. Triple-negative breast cancer (TNBC) remains a highly aggressive subtype lacking effective targeted therapies. Although chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment of hematological malignancies, its efficacy in solid tumors is hindered by the immunosuppressive … |
Clinical Program phase | PHASE_1 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | anti-mesothelin CAR-T cells (anti-mesothelin CAR-T cells) UTC Therapeutics Inc.·Solid Tumor, Adult 23 trials |
|---|---|
Overview Program | anti-mesothelin CAR-T cells |
Overview Company | UTC Therapeutics Inc. |
Overview Modality | CGT |
Overview Target | Solid Tumor, Adult |
Overview Indication | Solid Tumor, Adult |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Biogenic Selenium Nanoparticles Potentiate Anti-Mesothelin CAR-T Cell Therapy in a Syngeneic TNBC Model.. Triple-negative breast cancer (TNBC) remains a highly aggressive subtype lacking effective targeted therapies. Although chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment of hematological malignancies, its efficacy in solid tumors is hindered by the immunosuppressive … |
Toxicology CRS | Reported |
Clinical Safety signal | Biogenic Selenium Nanoparticles Potentiate Anti-Mesothelin CAR-T Cell Therapy in a Syngeneic TNBC Model.. Triple-negative breast cancer (TNBC) remains a highly aggressive subtype lacking effective targeted therapies. Although chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment of hematological malignancies, its efficacy in solid tumors is hindered by the immunosuppressive … |
Clinical Program phase | PHASE_1 |
추천 비교
추천 비교